Premature Ovarian Insufficiency (POI), previously termed premature menopause, affects 1–2% of women before age 40. It reflects declining ovarian hormone production and irregular or absent menstruation. Early diagnosis and appropriate hormone replacement preserve bone and cardiovascular health whilst fertility options are explored.
Diagnosis requires elevated follicle-stimulating hormone (FSH >25 mIU/mL) on repeat testing, combined with amenorrhea or oligomenorrhoea. Hormone replacement therapy (HRT)—oestrogen plus progestogen—restores physiological hormone levels, relieves vasomotor symptoms, and protects bone mineral density and cardiovascular function. Standard HRT regimens include transdermal patches, oral tablets, or vaginal preparations tailored to individual tolerability. Calcium and vitamin D supplementation supports skeletal health. Cardiovascular risk screening guides lipid management. For conception, assisted reproductive technology (ART) using donor eggs is the most reliable approach, with success rates of 40–50% per cycle depending on recipient age. Ovarian stimulation with high-dose gonadotropins may occasionally retrieve residual eggs from POI patients, though success is unpredictable.
Phytoestrogen-rich foods (soy, flax seeds, red clover) and herbal remedies including black cohosh, sage leaf, and Chinese herbal formulas are traditionally used for menopausal symptom relief. Evidence remains mixed; some trials show modest symptom improvement whilst others demonstrate minimal benefit beyond placebo. Acupuncture is investigated for vasomotor symptoms with variable outcomes across studies. Nutritional approaches emphasising antioxidants and micronutrient density reflect physiological support for ovarian function but cannot reverse established insufficiency.
Stem cell therapy is studied for POI, targeting restoration of ovarian follicle reserves and oestrogen production. Bone marrow-derived stem cells, adipose stem cells, and endometrial-derived stem cells are being evaluated in preclinical and early clinical research. Proposed mechanisms include paracrine signalling to suppress granulosa cell apoptosis and promote follicle development. Current outcomes are not yet predictable; clinical protocols remain experimental. Candidate assessment typically addresses women with severe ovarian suppression unsuitable for conventional HRT alone or wishing fertility restoration.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| FSH testing & diagnosis | Standard | Strong | €100–€250 | Low | Immediate |
| Hormone replacement therapy (HRT) | Standard | Strong | €50–€150/month | Low | Ongoing |
| Donor egg IVF | Standard | Strong | €6,000–€12,000 per cycle | Medium | 2–3 weeks |
| Herbal & phytoestrogen supplements | Alternative | Limited | €25–€75/month | Low | Ongoing |
| Acupuncture for symptom relief | Alternative | Moderate | €60–€120 per session | Low | Immediate |
| Ovarian stem cell transplant | Regenerative | Investigational | €18,000–€35,000 | Medium | 4–6 weeks |
| Ovarian stimulation for egg retrieval | Standard | Moderate | €3,000–€6,000 | Medium | 1–2 weeks |
Spontaneous pregnancy occurs in 5–10% of POI women, even with elevated FSH. Irregular ovulation may continue; contraception is necessary if pregnancy is not desired. Regular monitoring tracks ovarian activity.
HRT in POI carries different risk–benefit than in natural menopause due to younger age and absence of prior oestrogen exposure. Current evidence supports physiological-dose HRT to maintain health; individual cardiovascular and breast cancer risk assessment guides duration and regimen.
Donor egg IVF achieves live birth rates of 40–55% per cycle in recipients under 50, largely independent of recipient age. Outcomes depend on donor egg quality and uterine receptivity.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita